Journal of Clinical Endocrinology & Metabolism, Vol 54, 638-644, Copyright © 1982 by Endocrine Society

ARTICLES

Parathyroid hormone effects on serum 1,25-dihydroxyvitamin D levels in patients with X-linked hypophosphatemic rickets: evidence for abnormal 25-hydroxyvitamin D-1-hydroxylase activity

KW Lyles and MK Drezner

Patients with X-linked hypophosphatemic rickets (XLH) have normal or marginally low serum 1,25-dihydroxyvitamin D [1,25-(OH)2D] levels despite manifesting hypophosphatemia and phosphate depletion, which increase 1,25-(OH)2D production in many animal species. These data are consistent with the possibility that regulation of vitamin D metabolism is abnormal in XLH. However, controversy concerning the role of phosphate in the regulation of 25-hydroxyvitamin D-1-hydroxylase activity in man has raised doubt about this proposed defect. The presence of a defect in vitamin D metabolism could be established if hormonal or metabolic factors, other than hypophosphatemia, were unable to stimulate 25-hydroxyvitamin D-1-hydroxylase activity normally in patients with XLH. Thus, we compared the effects of parathyroid hormone infusion on serum 1,25-(OH)2D levels in patients with XLH and normals. In response to iv infusion of parathyroid extract (200 U at 0915 and 1700 h), the serum 1,25-(OH)2D concentration increased 218% above base line (from 34.0 +/- 3.0 to 108.8 +/- 2.5 pg/ml) in normals and only 68% (from 30.6 +/- 3.0 to 48.8 +/- 5.5 pg/ml) in patients with XLH. The disparate response occurred in spite of an equivalent increase in urinary cAMP excretion in the normals (from 3.00 +/- 0.14 to 8.70 +/- 0.25 mumol/g creatinine . 24 h) and XLH patients (from 3.10 +/- 0.39 to 8.30 +/- 1.0 mumol/g creatinine . 24 h) as well as equivalent decreases in the renal tubular maximum for the reabsorption of phosphate per liter glomerular filtrate (1.2 +/- 0.1 and 0.9 +/- 0.2 mg/dl, respectively). These observations support the possibility that regulation of vitamin D metabolism is abnormal in XLH.

This article has been cited by other articles:

				E. A. Imel and M. J. Econs Fibroblast Growth Factor 23: Roles in Health and Disease J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2565 - 2575. [Full Text] [PDF]

				B. Yuan, Y. Xing, R. L. Horst, and M. K. Drezner Evidence for Abnormal Translational Regulation of Renal 25-Hydroxyvitamin D-1{alpha}-Hydroxylase Activity in the Hyp-Mouse Endocrinology, August 1, 2004; 145(8): 3804 - 3812. [Abstract] [Full Text] [PDF]

				R. M. Savio, J. E. Gosnell, S. Posen, T. S. Reeve, and L. W. Delbridge Parathyroidectomy for Tertiary Hyperparathyroidism Associated With X-linked Dominant Hypophosphatemic Rickets Arch Surg, February 1, 2004; 139(2): 218 - 222. [Abstract] [Full Text] [PDF]

				H. S. Tenenhouse, J. Martel, C. Gauthier, M. Y. H. Zhang, and A. A. Portale Renal Expression of the Sodium/Phosphate Cotransporter Gene, Npt2, Is Not Required for Regulation of Renal 1{{alpha}}-Hydroxylase by Phosphate Endocrinology, March 1, 2001; 142(3): 1124 - 1129. [Abstract] [Full Text] [PDF]

				A. H. Zargar, B. A. Laway, S. R. Masoodi, F. A. Hakim, A. I. Wani, M. I. Bashir, and A. Mithal Hereditary hypophosphataemic rickets: report of a family from the Indian subcontinent Postgrad. Med. J., August 1, 1999; 75(886): 485 - 487. [Abstract] [Full Text]